Summit Therapeutics Inc. (NASDAQ: SMMT) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
14.69
+0.72+5.19%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | 0.09 | Insider Own | - | Shs Outstand | 797.75M | Perf Week | 7.22% |
| Market Cap | 11.14B | Forward P/E | - | EPS next Y | -1.10 | Insider Trans | 0.65% | Shs Float | 110.35M | Perf Month | -9.82% |
| Enterprise Value | 10.74B | PEG | 0.27 | EPS next Q | -0.28 | Inst Own | - | Short Float | 4.68% | Perf Quarter | -18.60% |
| Income | -877.56M | P/S | 0.00 | EPS this Y | -1351.41% | Inst Trans | - | Short Ratio | 6.84 | Perf Half Y | 0.79% |
| Sales | 57.00M | P/B | 17.24 | EPS next Y | 1.90% | ROA | -113.81% | Short Interest | 37.33M | Perf YTD | -20.18% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -204.33% | 52W High | 31.61 -53.54% | Perf Year | -51.05% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -134.14% | 52W Low | 12.89 13.96% | Perf 3Y | 615.90% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 4.29% 5.68% | Perf 5Y | 90.45% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | 136.00% | Oper. Margin | 0.00% | ATR (14) | 0.79 | Perf 10Y | 99.14% |
| Dividend Ex-Date | - | Quick Ratio | 6.96 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 49.25 | Recom | 2.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.96 | EPS Q/Q | 63.16% | SMA20 | 0.55% | Beta | -1.32 | Target Price | 26.00 |
| Payout | 0.00% | Debt/Eq | 0.03 | Sales Q/Q | - | SMA50 | -3.07% | Rel Volume | 0.43 | Prev Close | 13.96 |
| Employees | 265 | LT Debt/Eq | 0.03 | Earnings | Oct 19 | SMA200 | -17.17% | Avg Volume | 4.94M | Price | 14.69 |
| IPO Date | Mar 05, 2015 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -2.04% - | Net Debt/EBITDA | 0.47 | Volume | 2,124,226 | Change | 5.19% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-24-26 | Reiterated | Jefferies | Hold | $17 → $15 |
| Jul-24-26 | Reiterated | Stifel Nicolaus | $45 → $38 | |
| Jul-24-26 | Reiterated | Guggenheim | Buy | $38 |
| May-22-26 | Downgrade | HC Wainwright & Co. | Buy → Neutral | |
| May-04-26 | Reiterated | HC Wainwright & Co. | Buy | $30 → $23 |
| May-01-26 | Reiterated | Piper Sandler | Neutral | $40 → $16 |
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold | |
| Feb-24-26 | Reiterated | HC Wainwright & Co. | Buy | $40 → $30 |
| Jan-14-26 | Reiterated | Piper Sandler | $40 | |
| Dec-17-25 | Reiterated | Summit Redstone Partners | $13 → $18 |
Latest News
Aug-07-26
Aug-06-26
Aug-06-2604:07PM
Aug-05-26
Aug-05-2607:22AM
07:00AM
Aug-04-26
Aug-04-2608:15AM
Aug-03-26
Aug-03-2604:16AM
Jul-31-26
Jul-31-2601:22PM
Jul-27-26
Jul-27-2608:52AM
Jul-24-26
Jul-24-2603:32PM
11:53AM
Jul-23-26
06:07PM
Summit Therapeutics Q2 Earnings Call Highlightsmarketbeat.com
04:05PM
11:36AM
Company
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 1/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 57 | 0 | 0 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | — | — | — | |
| Gross Profit | 57 | 0 | 0 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 14 | 557 | 48 | — | — | — | — | — | — | |
| Research and Development | 38 | 538 | 132 | — | — | — | — | — | — | |
| Other Operating Expense | 2 | -1 | 1 | — | — | — | — | — | — | |
| Operating Income | 22 | -1,094 | -181 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 9 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -9 | 15 | 12 | — | — | — | — | — | — | |
| Net Income Before Taxes | 13 | -1,080 | -177 | — | — | — | — | — | — | |
| Income Taxes | -3 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | 7 | -1,080 | -177 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 15 | -1,080 | -177 | — | — | — | — | — | — | |
| Net Income | 7 | -1,080 | -177 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.09 | -1.44 | -0.25 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.09 | -1.44 | -0.25 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.09 | -1.44 | -0.25 | — | — | — | — | — | — | |
| EBITDA | -2 | -1,079 | -168 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 163.17 | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 39.42 | — | — | — | — | — | — | — | — | |
| Gross Margin | 100.00 | — | — | — | — | — | — | — | — | |
| Operating Margin | 38.60 | — | — | — | — | — | — | — | — | |
| Net Margin | 12.28 | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 153 | 748 | 714 | — | — | — | — | — | — | |
| Market Capitalization | 2,247 | 13,083 | 12,745 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Zanganeh Mahkam | Co-Chief Executive Officer | Jun 12 '26 | Buy | 13.12 | 3,810,000 | 49,987,200 | 573,883,879 | Jun 12 |
| DUGGAN ROBERT W | Co-Chief Executive Officer | Jun 12 '26 | Buy | 13.12 | 3,810,000 | 49,987,200 | 573,883,879 | Jun 12 |
| Soni Manmeet Singh | COO and CFO | Jun 04 '26 | Buy | 14.45 | 50,000 | 722,250 | 3,123,603 | Jun 04 |
| DUGGAN ROBERT W | Co-Chief Executive Officer | Jun 04 '26 | Buy | 14.60 | 100,000 | 1,460,000 | 25,824,474 | Jun 04 |
| Zanganeh Mahkam | Co-Chief Executive Officer | Jun 04 '26 | Buy | 14.60 | 100,000 | 1,460,000 | 25,824,474 | Jun 04 |
| Xia Yu | Director | Oct 21 '25 | Buy | 18.74 | 533,617 | 9,999,983 | 32,057,147 | Oct 23 |
| DUGGAN ROBERT W | Co-Chief Executive Officer | Oct 21 '25 | Buy | 18.74 | 26,680 | 499,983 | 76,680 | Oct 23 |
| Zanganeh Mahkam | Co-Chief Executive Officer | Oct 21 '25 | Buy | 18.74 | 26,680 | 499,983 | 76,680 | Oct 23 |
| Zanganeh Mahkam | Co-Chief Executive Officer | Sep 11 '25 | Buy | 18.07 | 5,000 | 90,350 | 556,093,090 | Sep 11 |
| DUGGAN ROBERT W | Co-Chief Executive Officer | Sep 11 '25 | Buy | 18.07 | 5,000 | 90,350 | 556,093,090 | Sep 11 |
| Zanganeh Mahkam | Co-Chief Executive Officer | Sep 10 '25 | Buy | 17.68 | 333,394 | 5,894,406 | 556,088,090 | Sep 11 |
| DUGGAN ROBERT W | Co-Chief Executive Officer | Sep 10 '25 | Buy | 17.68 | 333,394 | 5,894,406 | 556,088,090 | Sep 11 |
| Zanganeh Mahkam | Co-Chief Executive Officer | May 30 '25 | Option Exercise | 2.64 | 74,545 | 196,799 | 555,754,696 | Jun 02 |
| DUGGAN ROBERT W | Co-Chief Executive Officer | May 30 '25 | Option Exercise | 2.64 | 74,545 | 196,799 | 555,754,696 | Jun 02 |
| Zanganeh Mahkam | Co-Chief Executive Officer | Apr 08 '25 | Option Exercise | 1.58 | 7,970,110 | 12,592,774 | 555,680,151 | Apr 09 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.